SEEKING ALPHA (12/28/2017): "CV Sciences, for example, has been focusing on making its financials much more appealing by clearing out its debt obligations through repaying note holders in cash. Earlier in December, the company made a payment to the holder of $770,000 worth of convertible debt and intends to continue doing so in order to prevent any additional dilution to the company's market.
The company's third quarter results could be a clear indication for future growth as well. Based on its most recent filing, CV Sciences was able to increase sales by 90% on a year-over-year basis with a sizeable 112% increase on a quarterly basis compared with the third quarter of 2016. In light of this fact, it doesn't come as a surprise that due to its drug development segment, the company incurred significant expenses from SG&A for the quarter. This largely contributed to its reported net loss. But hopefully this investment pays off in 2018."